Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Short-term Investments (2016 - 2026)

Pharma-Bio Serv filings provide 12 years of Short-term Investments readings, the most recent being $4.8 million for Q1 2026.

  • On a quarterly basis, Short-term Investments fell 6.45% to $4.8 million in Q1 2026 year-over-year; TTM through Jan 2026 was $4.8 million, a 6.45% decrease, with the full-year FY2025 number at $7.5 million, up 25.05% from a year prior.
  • Short-term Investments hit $4.8 million in Q1 2026 for Pharma-Bio Serv, down from $7.5 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $11.7 million in Q3 2023 to a low of $4.5 million in Q4 2023.
  • Median Short-term Investments over the past 4 years was $6.8 million (2025), compared with a mean of $7.2 million.
  • Biggest five-year swings in Short-term Investments: surged 80.98% in 2024 and later plummeted 45.89% in 2025.
  • Pharma-Bio Serv's Short-term Investments stood at $4.5 million in 2023, then skyrocketed by 31.93% to $6.0 million in 2024, then grew by 25.05% to $7.5 million in 2025, then crashed by 35.84% to $4.8 million in 2026.
  • The last three reported values for Short-term Investments were $4.8 million (Q1 2026), $7.5 million (Q4 2025), and $6.8 million (Q3 2025) per Business Quant data.